Zymic Technology (ZYMIQ) Q2 2025 earnings summary

Executive summary

• Net sales for Q2 2025 were SEK 334 thousand, nearly flat year-over-year, while H1 2025 net sales rose 54% to SEK 1,146 thousand compared to H1 2024.

• Loss after tax for Q2 2025 was SEK -3,149 thousand, a slight improvement from SEK -3,157 thousand in Q2 2024.

• The company is transitioning from development to market, focusing on building a sustainable business model reinvesting product revenues into research.

• Significant product launches and international expansion, including new sales to Hungary and Denmark, and presence at major trade events in Asia.

Financial highlights

• H1 2025 net sales increased 54% year-over-year to SEK 1,146 thousand.

• Q2 2025 gross margin was 83%, up from 48% in Q2 2024.

• Cash and cash equivalents at period end were SEK 888 thousand, down from SEK 4,969 thousand a year earlier.

• Q2 2025 operating loss was SEK -3,148 thousand, similar to Q2 2024.

• Earnings per share for Q2 2025 were SEK -0.37, compared to SEK -0.40 in Q2 2024.

Outlook and guidance

• Strategic focus is shifting towards a business-driven organization and delivery of research.

• Ongoing discussions with financial advisors in preparation for a planned IPO in Q4 2025.

• Management is confident in achieving set goals despite macroeconomic uncertainties.